Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Expands Hep C Portfolio With LG Life Sciences Deal

This article was originally published in PharmAsia News

Executive Summary

Gilead Sciences is gaining a Phase II pan-caspase inhibitor for hepatitis C through a licensing agreement with LG Life Sciences worth up to $202 million announced Nov. 7

You may also be interested in...



LG Life Science Tops R&D Investment List of Korea-Listed Pharmas

SEOUL - Of the 37 local Korean pharmas listed on Korea's main KOSPI stock market, LG Life Science topped local pharmas in R&D investment last year in both scale and in proportion to its sales, according to a report released by a lawmaker in an Oct. 6 National Assembly session

LG Life Science Tops R&D Investment List of Korea-Listed Pharmas

SEOUL - Of the 37 local Korean pharmas listed on Korea's main KOSPI stock market, LG Life Science topped local pharmas in R&D investment last year in both scale and in proportion to its sales, according to a report released by a lawmaker in an Oct. 6 National Assembly session

Korean LG Life Sciences Plans BLA Submission For Biosimilar Somatropin To U.S. FDA

SEOUL - South Korea's LG Life Sciences completed its Phase III clinical trial of its slow-release recombinant human growth hormone somatropin weekly injection for treating adults with growth hormone deficiency, and is getting its biologics license application ready for U.S. FDA for the new formulation

Related Content

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel